Download biomedica product list
NT-proCNP a potential biomarker for osteosarcoma
Osteosarcoma (OS) is the most prevalent form of bone cancer affecting children and adolescents, often during periods of rapid bone growth (1). The primary pathophysiological process involves various potential genetic factors associated with bone formation that contribute to malignant progression and the spread of the disease (2). In recent years, plasma NT-proCNP levels and height velocity in children, along with CNP itself, have been recognized as emerging new markers of growth during childhood (3). CNP is essential for linear growth, being produced in the growth plate and acting via a paracrine signaling mechanism (4). The C-type natriuretic peptide (CNP) and its receptor, NPR-B, are essential in the process of endochondral bone development and growth. CNP functions as a local regulator, promoting bone growth via its receptor, NPR-B, a guanylyl cyclase. The fragment NT-proCNP, derived from CNP, serves as a valuable biomarker for tracking linear growth in children, especially during puberty (5).
NT-proCNP a potential biomarker for osteosarcoma
In a recent study researchers examined serum N-terminal pro C-type natriuretic peptide (NT-proCNP) at diagnosis and remission in children with osteosarcoma (6). The Biomedica NT-proCNP ELISA (BI-20812) was employed in the study.
Key findings:
NT-proCNP concentrations
– were significantly lower in OS patients compared to controls
– were elevated at diagnosis compared to remission phases
– NT-proCNP could serve as a potential biomarker in monitoring disease progression and remission status in OS patients
NT-proCNP ELISA kit (cat.no. BI-20812)
-Trusted – widely cited in over 50 publications
-Validated – following quality guidelines (download validation data here)
Literature
- Osteosarcoma. Eaton BR, Schwarz R, Vatner R, Yeh B, Claude L, Indelicato DJ, Laack N. Pediatr Blood Cancer. 2021 May;68 Suppl 2:e28352. doi: 10.1002/pbc.28352. Epub 2020 Aug 11. PMID: 32779875.
- Osteosarcoma. Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ, Gorlick R. Nat Rev Dis Primers. 2022 Dec 8;8(1):77. doi: 10.1038/s41572-022-00409-y. Erratum in: Nat Rev Dis Primers. 2022 Dec 30;8(1):82. doi: 10.1038/s41572-022-00416-z. PMID: 36481668.
- Plasma C-Type Natriuretic Peptide: Emerging Applications in Disorders of Skeletal Growth – PubMed (nih.gov) Espiner E, Prickett T, Olney R. Horm Res Paediatr. 2018;90(6):345-357. doi: 10.1159/000496544. Epub 2019 Mar 7. PMID: 30844819.
- Dynamic response of C-type natriuretic peptide and its aminoterminal propeptide (NTproCNP) to growth hormone treatment in children with short stature. Olney RC et al., Clin Endocrinol, 2016; 85(4):561-568.
- C-type natriuretic peptide and its contribution to bone growth. Kulik-Rechberger B, Trojanowska-Szostek M Ann Agric Environ Med. 2022 Jun 24;29(2):252-257. doi: 10.26444/aaem/140076. Epub 2021 Jul 26. PMID: 35767759.
-
Investigation of serum C-type natriuretic peptide concentration at diagnosis and remission in pediatric osteosarcomas. Özdemir Sİ, Akcan G, Tufan AÇ, Erdem AY, Çakmakcı S, Özyörük D, Sarı N, Tufan NLŞ, İlhan İE. Eur J Pediatr. 2025 Jan 6;184(1):116. doi: 10.1007/s00431-024-05949-x. PMID: 39757264.